(19)
(11) EP 4 448 110 A2

(12)

(88) Date of publication A3:
03.08.2023

(43) Date of publication:
23.10.2024 Bulletin 2024/43

(21) Application number: 22908118.7

(22) Date of filing: 08.12.2022
(51) International Patent Classification (IPC): 
A61P 35/00(2006.01)
C07D 401/14(2006.01)
G16B 15/00(2019.01)
 A61K 31/33(2006.01)
G16B 5/00(2019.01)
(52) Cooperative Patent Classification (CPC):
C12N 9/14; C12Y 306/05002; A61K 31/196; A61K 31/506; A61K 31/4174; A61K 31/704; A61K 31/454
(86) International application number:
PCT/TR2022/051452
(87) International publication number:
WO 2023/113739 (22.06.2023 Gazette 2023/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 15.12.2021 TR 202120041

(71) Applicant: Istanbul Medipol Universitesi
Istanbul (TR)

(72) Inventors:
  • KA MER, Ramazan
    Istanbul (TR)
  • ILTER, Metchan
    Istanbul (TR)
  • SENSOY, Özge
    Istanbul (TR)
  • KARAKA , Nihal
    Istanbul (TR)
  • TOPÇU, Ozan
    Istanbul (TR)

(74) Representative: Mutlu, Aydin 
Invokat Intellectual Property Services Ltd. Kartaltepe Mh. Yildiztepe Sk. No:6-Bakirköy
34145 Istanbul
34145 Istanbul (TR)

   


(54) NOVEL THERAPEUTIC MOLECULES TARGETING THE H-RAS ISOFORM WITH G12D MUTATION INVOLVED IN CANCER FORMATION